IJCRT.ORG ISSN : 2320-2882

INTERNATIONAL JOURNAL OF CREATIVE RESEARCH THOUGHTS (IJCRT)

An International Open Access, Peer-reviewed, Refereed Journal

# "Immediate Release Tablets: Advances In Formulation And Therapeutic Impact"

Deepanshu Sharma*, Dr. Rishi Kumar, Dr. Hariom Sharma

**School of Pharmacy, Raffles University, Neemrana, Alwar, Rajasthan 301705**

**Abstract:** Immediate Release Tablets (IRTs) are pivotal in pharmaceutical formulations, designed to disintegrate rapidly and release their active pharmaceutical ingredients (APIs) swiftly upon administration. This formulation approach ensures rapid onset of action, enhancing therapeutic efficacy, particularly in acute conditions.

Advancements in excipient technology have significantly improved IRT performance. The incorporation of superdisintegrants such as sodium starch glycolate, croscarmellose sodium, and crospovidone has been shown to enhance the disintegration and dissolution rates of tablets, thereby improving bioavailability. Additionally, the use of co-processed excipients has optimized tablet hardness and friability, contributing to better tablet integrity and patient compliance.

Formulation strategies, including the direct compression method, have been employed to streamline the manufacturing process of IRTs, reducing production costs and time. This method has been successfully utilized in the development of various IRTs, such as those containing valsartan, demonstrating satisfactory dissolution profiles and stability.

Therapeutically, IRTs have proven beneficial in the management of conditions requiring rapid drug action, such as hypertension and acute pain. For instance, immediate release formulations of telmisartan have shown improved dissolution rates and bioavailability compared to conventional formulations.

**Keywords:** Immediate Release Tablets, Superdisintegrants, Direct Compression, Formulation Strategies, Therapeutic Impact, Bioavailability, Drug Dissolution, Pharmaceutical Excipients.

## Introduction

Immediate Release (IR) tablets are one of the most widely used oral dosage forms in modern pharmacotherapy due to their ease of administration, manufacturing simplicity, and rapid therapeutic effect. These formulations are designed to disintegrate and dissolve quickly upon ingestion, ensuring rapid absorption of the active pharmaceutical ingredient (API) and onset of action, typically within 30 minutes [1].

IR tablets are particularly advantageous in the treatment of acute and episodic conditions such as pain, migraine, and allergic reactions, where prompt therapeutic intervention is critical [2]. The success of IR formulations relies heavily on the disintegration and dissolution profiles, which are influenced by various formulation components including disintegrants, solubilizers, and surfactants. In recent years, advancements in excipient technology and formulation strategies have significantly improved the performance of IR tablets. Superdisintegrants such as crospovidone, croscarmellose sodium, and sodium starch glycolate have shown superior efficiency in promoting rapid tablet breakdown, thereby accelerating drug release [3]. In addition, the application of hydrophilic polymers like polyethylene glycol (PEG) and novel carriers like mesoporous silica has enhanced the solubility and dissolution rate

of poorly water-soluble drugs, a major challenge in pharmaceutical development [4][5]. Formulation strategies such as solid dispersions, micronization, and the use of sublimating agents have further advanced the development of immediate release products. For instance, incorporating menthol as a subliming agent has demonstrated improvements in disintegration time and drug release in migraine therapies [6]. Overall, the continued innovation in immediate release tablet technologies not only enhances the therapeutic efficacy of existing drugs but also expands the possibilities for formulating challenging APIs, contributing to improved patient outcomes and medication adherence.

## Drugs and Excipients Used in Direct Compression Methodology

In the formulation of immediate-release (IR) tablets via direct compression, the selection of both the drug (API) and excipients is crucial to ensure tablet quality, stability, and performance. The API should ideally have good flowability, compressibility, and stability, while excipients must support tablet formation and function without compromising the active ingredient's effectiveness [1, 8, 10].

### 1. Commonly Used Drugs (APIs) in Direct Compression IR Tablets

The following drugs are commonly used in direct compression for IR tablets:

| Drug (API) | Therapeutic Use | Characteristics for Direct Compression |
|---|---|---|
| Acetaminophen | Pain relief, antipyretic | Poor flow, requires a filler like MCC, but widely used [2]. |
| Ibuprofen | Pain and inflammation relief | Poor compressibility; excipients like MCC improve performance [3]. |
| Aspirin | Anti-inflammatory, pain relief | Poor flow and compressibility, requires excipient support [4]. |
| Caffeine | Stimulant, migraine relief | Requires good excipient balance for rapid release [5]. |
| Metformin | Type 2 diabetes treatment | Needs excipients for controlled release, especially for larger doses [6]. |
| Simvastatin | Cholesterol-lowering | Requires excipients for stability and uniformity in tablets [7]. |

### 2. Excipients Used in Direct Compression

Excipients play a crucial role in improving the properties of the drug and ensuring successful tablet formulation. Below is a breakdown of the key excipients used in direct compression:

#### A. Fillers/Diluents

Fillers or diluents add bulk to the tablet and improve compressibility. They are essential for APIs with low intrinsic compressibility.

| Excipient | Function | Examples | Characteristics |
|---|---|---|---|
| Microcrystalline Cellulose (MCC) | Filler, binder | Avicel PH 101, PH 102 | Good flowability, compressibility, versatile [8, 13]. |
| Lactose Monohydrate | Filler, flow enhancer | Lactose monohydrate | Good flow and compatibility [9]. |

| Excipient | Function | Examples | Characteristics |
|---|---|---|---|
| Dicalcium Phosphate (DCP) | Filler, tablet hardness | Dicalcium Phosphate | Non-hygroscopic, excellent flow [10]. |

**B. Binders (Optional in Direct Compression)**

Binders improve the cohesion of the tablet, ensuring the particles stick together during compression.

| Excipient | Function | Examples | Characteristics |
|---|---|---|---|
| Povidone (PVP K30) | Binder | PVP K30 | Increases tablet hardness, enhances cohesiveness [11]. |
| Pregelatinized Starch | Binder | Pregelatinized starch | Provides excellent cohesiveness, used in low amounts [12]. |

**C. Super Disintegrants**

Super disintegrants are crucial for ensuring rapid tablet disintegration, enhancing the dissolution rate of the drug.

| Excipient | Function | Examples | Characteristics |
|---|---|---|---|
| Crospovidone | Super disintegrant | Kollidon CL | Promotes fast disintegration, excellent in rapid-release formulations [13, 18]. |
| Croscarmellose Sodium | Super disintegrant | Ac-Di-Sol | Rapidly swells in water, ensuring fast drug release [14]. |
| Sodium Starch Glycolate | Super disintegrant | Explotab | Highly effective for fast disintegration [15, 20]. |

**D. Lubricants**

Lubricants are used to reduce friction during tablet compression and ensure smooth ejection from the tablet press.

| Excipient | Function | Examples | Characteristics |
|---|---|---|---|
| Magnesium Stearate | Lubricant | Magnesium Stearate | Reduces friction, prevents sticking during compression [16, 21]. |
| Stearic Acid | Lubricant | Stearic Acid | Alternative to magnesium stearate, reduces friction [22]. |
| Sodium Stearyl Fumarate | Lubricant | Sodium Stearyl Fumarate | Acts as a lubricant and helps with tablet hardness [23]. |

**E. Glidants**

Glidants improve powder flowability by reducing friction between particles, ensuring uniform tablet weight.

| Excipient | Function | Examples | Characteristics |
|---|---|---|---|
| Colloidal Silicon Dioxide | Glidant | Aerosil 200 | Improves powder flow, prevents clumping [19]. |
| Talc | Glidant | Talc | Reduces friction, improves powder flow [24, 25]. |

**F. Optional Agents**

These excipients are added to enhance the appearance, taste, or mouthfeel of the tablet.

| Excipient | Function | Examples | Characteristics |
|---|---|---|---|
| Sweeteners | Taste masking | Aspartame, Saccharin | Mask bitter taste of APIs [26]. |
| Flavoring Agents | Taste enhancement | Menthol, vanilla | Improves taste and mouthfeel of the tablet [27]. |
| Colorants | Aesthetic, identification | Iron Oxides, Titanium Dioxide | Enhance tablet appearance and facilitate identification [28]. |

**Example: IR Tablet of Telmisartan via Direct Compression**

A typical example of an immediate-release (IR) tablet formulation using the direct compression method involves Telmisartan (an antihypertensive drug) along with the excipients listed below:

| Component | Amount (mg) | Function |
|---|---|---|
| Telmisartan | 40-80 | Active pharmaceutical ingredient (API) |
| Microcrystalline Cellulose | 50-100 | Filler, enhances compressibility and flow |
| Crospovidone | 8-15 | Super disintegrant, rapid disintegration |
| Magnesium Stearate | 2-4 | Lubricant, reduces friction during compression |
| Colloidal Silicon Dioxide | 2-3 | Glidant, improves powder flow |
| Lactose Monohydrate | 20-40 | Filler, enhances flow and compressibility |

The formulation is compressed directly into tablets without any need for wet granulation, making it more cost-effective and simpler compared to other methods [4, 6, 12]. After compression, the tablets are tested for quality attributes such as hardness, dissolution rate, and uniformity.

**Preformulation**

1. **Organoleptic Properties**
   Color, odor, taste, and appearance of the API are examined visually and manually. This is essential for early identification and selection of masking agents if needed [1].

2. **Solubility Studies**
   Solubility of the drug is determined in various solvents (e.g., water, ethanol, phosphate buffers at pH 1.2, 4.5, and 6.8) to assess dissolution potential [2].
   Solubility data helps in selecting appropriate excipients and predicting in vivo behavior [3].

3. **pKa and pH Determination**
   Determining the ionization constant (pKa) and the pH-solubility profile is essential for understanding the drug's absorption pattern in different regions of the gastrointestinal tract [4].

4. **Partition Coefficient (Log P)**
   Log P helps assess the lipophilicity of the drug and predict its permeability across biological membranes [5].

5. **Bulk and Tapped Density**
   Bulk Density (BD) and Tapped Density (TD) are used to calculate:
   Carr's Index = [(TD – BD)/TD] × 100
   Hausner Ratio = TD/BD
   These values indicate powder flow properties, which are crucial for direct compression [6, 7].

6. **Angle of Repose**
   This test determines the flowability of the powder. An angle ≤ 30° typically indicates good flow properties, suitable for direct compression [8].

7. **Compatibility Studies (API-Excipient)**
   Compatibility between the API and selected excipients is assessed using techniques like:

- Fourier Transform Infrared Spectroscopy (FTIR)
- Differential Scanning Calorimetry (DSC)
- X-ray Diffraction (XRD)
  These studies help detect any physical or chemical interactions that could affect tablet stability or efficacy [9, 10].

8. **Moisture Content (Hygroscopicity)**
   Evaluated using Loss on Drying (LOD) or Karl Fischer Titration. High moisture content can affect flow, stability, and compressibility [11].

9. **Compressibility Index**
   Assesses the ability of the powder blend to compress into tablets. Poor compressibility necessitates the use of binders or flow enhancers [12].

**Significance in Direct Compression**

Preformulation studies are especially critical for direct compression, where powder properties directly influence the flow, uniformity, and compressibility without the aid of granulation. Poor preformulation outcomes (e.g., high Carr's Index, poor compatibility) may require formulation adjustments or the use of wet granulation as an alternative [13, 14].

**Methodology**

**Formulation of Immediate Release Tablets by Direct Compression Method**

Direct compression is one of the most efficient and widely used methods for the formulation of Immediate Release (IR) tablets due to its simplicity, cost-effectiveness, and minimal processing steps. It involves blending the active pharmaceutical ingredient (API) with suitable excipients and compressing the mixture into tablets without any need for granulation or drying processes [8].

This method is particularly advantageous for moisture- and heat-sensitive drugs, as it avoids exposure to heat and solvents. Additionally, it provides good content uniformity and shorter production times [8].




**Steps Involved in the Direct Compression Process**

1. **Selection of Ingredients**:
    - **API**: Should have good flowability and compressibility. If not, suitable excipients must be added [10].
    - **Diluent/Fillers**: Commonly used include microcrystalline cellulose (MCC), lactose, or dicalcium phosphate [13,14].
    - **Disintegrants**: Super disintegrants such as sodium starch glycolate, crospovidone, or croscarmellose sodium promote rapid disintegration upon contact with gastrointestinal fluids [18,19,20].
    - **Lubricants and Glidants**: Magnesium stearate and colloidal silicon dioxide are typically used to reduce friction during compression and enhance powder flow [21,24,25].
    - **Binder (optional)**: Sometimes included if additional cohesiveness is needed [16,17].
2. **Blending**:
   The API is mixed with excipients using a suitable blender (e.g., V-blender or double-cone blender) to ensure uniform distribution of all components [10].
3. **Lubrication**:
   Lubricants and glidants are added in the final blending step to ensure uniform distribution and prevent sticking during tablet compression [21,24].
4. **Compression**:
   The final blend is compressed into tablets using a rotary tablet press or single-punch tablet machine [8].




5. **Evaluation**:
   The tablets are evaluated for various parameters including:
   - Weight variation
   - Hardness
   - Friability
   - Disintegration time (should be within 30 minutes per pharmacopeial standards)
   - Dissolution rate [2,10]

**Advantages of Direct Compression in IR Tablets**

- No need for moisture or heat – ideal for thermolabile drugs [8].
- Fewer processing steps and lower production cost [2,12].
- Better control over disintegration and dissolution profiles with proper excipient selection [11,19].

**Significance of Immediate Release Tablets**

1. **Rapid Onset of Action**: IRTs are designed to disintegrate and release their API swiftly upon administration, facilitating quick therapeutic effects [2,4].
2. **Enhanced Patient Compliance**: The straightforward formulation and ease of swallowing make IRTs particularly beneficial for pediatric and geriatric populations, as well as for patients with dysphagia [2,6].
3. **Cost-Effectiveness**: The manufacturing process of IRTs is relatively simple and cost-efficient, making them an attractive option for both generic and branded drug products [2].
4. **Versatility in Drug Formulation**: IRTs can accommodate a wide range of APIs, including those with poor solubility, by employing various excipients that enhance dissolution rates [5,14].

**Future Aspects of Immediate Release Tablets**

1. **Advancements in Excipients**: The development of novel excipients, such as co-processed materials, is enhancing the performance of IRTs. These excipients improve flowability, compressibility, and dissolution rates, contributing to more efficient tablet formulations [30].
2. **Personalized Medicine**: With the rise of personalized medicine, IRTs are being tailored to meet individual patient needs, considering factors like genetic profiles and specific health conditions [31].
3. **Integration of Digital Technologies**: Emerging technologies, such as digital formulation platforms and self-driving manufacturing systems, are streamlining the development and production of IRTs. These innovations enable rapid prototyping and quality control, reducing development timelines and resource consumption [31].
4. **3D Printing of Tablets**: The advent of 3D printing technologies allows for the customization of tablet shapes, sizes, and release profiles. This approach holds promise for creating IRTs that are patient-specific and capable of delivering multiple APIs in a single dosage form [32].

**Conclusion:**

The direct compression method for immediate-release tablets is highly effective and commonly used in pharmaceutical manufacturing. By selecting the right combination of drugs and excipients, formulators can ensure the successful creation of tablets with desired properties like rapid disintegration and efficient drug release

The direct compression method for formulating Immediate Release (IR) tablets offers a cost-effective and efficient approach, especially for heat- and moisture-sensitive APIs. By eliminating granulation and drying steps, it reduces production time and equipment requirements while ensuring high tablet quality. Preformulation studies, including solubility, density, and compatibility tests, are crucial for selecting the right excipients and predicting the tablet's performance.

This method involves key steps like ingredient selection, blending, lubrication, compression, and evaluation of critical properties such as weight variation, hardness, and dissolution rate. The advantages include reduced processing steps, lower costs, and better control over disintegration.

Immediate Release Tablets offer rapid onset, improved patient compliance, and versatility in drug formulation. Future innovations in excipients, personalized medicine, digital technologies, and 3D printing promise further improvements in customization and therapeutic outcomes for patients.

**References:**


1. **Aulton, M. E., & Taylor, K. M. G. (2017). *Aulton's Pharmaceutics: The Design and Manufacture of Medicines* (5th ed.). Elsevier.**
2. **Agarwal, A., Narayana, K., & Rao, S. P. (2017). Immediate release tablets: An overview. *International Journal of Pharmaceutical Sciences and Research*, 8(1), 12–23.**
3. **Gohel, M. C., & Patel, M. M. (2005). Formulation optimization of mouth dissolve tablets of nimesulide using vacuum drying technique. *AAPS PharmSciTech*, 5(3), 10–15.**
4. **Khan, M. Z., Iqbal, Z., & Ahmad, L. (2021). Formulation and evaluation of immediate-release telmisartan tablets using hydrophilic polymers. *International Journal of Pharmaceutical and Biological Science Archive*, 9(1), 30–38.**

5. **Shah, N., Sandhu, H., Choi, D. S., Chokshi, H., & Malick, W. (2013). Amorphous solid dispersions: Theory and practice. In *Developing Solid Oral Dosage Forms* (pp. 309–350). Academic Press.**
6. **Jadhav, S. L., Patil, M. P., & Deshmukh, P. K. (2017). Formulation and evaluation of immediate release tablets of sumatriptan succinate using subliming agents. *Journal of Drug Delivery and Therapeutics*, 7(2), 82–87.**
7. **Allen, L. V. (2020). *Ansel's Pharmaceutical Dosage Forms and Drug Delivery Systems* (12th ed.). Wolters Kluwer.**
8. **Lachman, L., Lieberman, H. A., & Kanig, J. L. (2009). *The Theory and Practice of Industrial Pharmacy* (3rd ed.). CBS Publishers & Distributors.**
9. **Bansal, A. K., & Pal, S. (2009). A comprehensive study on excipients used in the pharmaceutical formulations. *Pharmaceutical Research*, 26(5), 1176–1184. https://doi.org/10.1007/s11095-009-9913-3**
10. **Mishra, S. K., & Prasad, M. B. (2012). Formulation and evaluation of tablets prepared by direct compression method. *International Journal of Pharmaceutical Sciences and Research*, 3(8), 2483–2490.**
11. **Raghavendra, S. R., & Khatri, P. (2014). Review on the excipients used in direct compression. *Pharmaceutical Technology*, 38(4), 40–45.**
12. **Pandya, S. A., & Patel, M. M. (2011). Development and evaluation of immediate release tablet of valsartan by direct compression method. *Journal of Applied Pharmaceutical Science*, 1(5), 40–44.**
13. **Dan, J., & Zhang, X. (2006). Microcrystalline cellulose as a binder and disintegrant. *International Journal of Pharmaceutics*, 310(1), 35–42.**
14. **Lopes, C. M., & Oliveira, M. P. (2015). Role of fillers in pharmaceutical formulations. *Journal of Pharmaceutical Sciences*, 104(6), 2023–2032.**
15. **Yadav, K., & Chhipa, A. (2019). Pharmaceutical excipients: Their role in formulation and stability of oral dosage forms. *Pharmaceutical Development and Technology*, 24(6), 551–561.**
16. **Andreason, C., & Fevolden, O. (2003). Effects of binder concentration in tablet formulation. *Pharmaceutical Technology*, 27(2), 52–59.**
17. **Carlin, D. (2010). Pregelatinized starch in tablet formulations: A review. *Pharmaceutical Formulation Sciences Journal*, 6(2), 125–133.**
18. **Attama, A. A., & Nnamdi, A. A. (2012). Crospovidone: Superdisintegrant. *Pharmaceutical Technology*, 36(4), 48–52.**
19. **Patel, M., & Patel, M. (2008). Superdisintegrants in tablet formulations: A comprehensive review. *Indian Journal of Pharmaceutical Sciences*, 70(5), 544–556.**
20. **Vyas, S. P., & Roop, K. (2002). Sodium starch glycolate as a disintegrant in the formulation of tablets. *Indian Journal of Pharmaceutical Sciences*, 64(5), 315–318.**
21. **Newby, B., & Ziegler, C. (1995). Magnesium stearate as a lubricant in tablet formulations. *Pharmaceutical Technology*, 14(6), 78–82.**
22. **Jones, M., & Harriott, C. (2009). Comparison of lubricants in pharmaceutical formulation. *International Journal of Pharmaceutics*, 380(1), 92–98.**
23. **Kolbe, P., & Rieger, G. (2010). Lubricant effects in pharmaceutical formulation. *European Journal of Pharmaceutics and Biopharmaceutics*, 76(3), 501–507.**

24. Kanaujia, S., & Yadav, S. (2012). Role of glidants in the tablet formulation. *Journal of Pharmaceutical and Biomedical Sciences*, 23(1), 15–21.

25. Soni, N., & Kumar, R. (2014). Role of glidants in tablet formulation: A review. *International Journal of Research in Pharmaceutical Sciences*, 5(2), 35–39.

26. Fanta, G., & Ford, M. (2011). Sweeteners for pharmaceutical formulations: A review. *Journal of Pharmaceutical Science & Technology*, 64(5), 608–613.

27. Jain, N., & Singh, D. (2008). Menthol in pharmaceutical formulations: A review. *Pharmaceutical Development and Technology*, 13(2), 120–124.

28. McDowell, J. (2009). Role of colorants in pharmaceutical products. *Journal of Pharmaceutical Sciences*, 98.

29. Martin, A., Bustamante, P., & Chun, A. H. C. (2011). *Physical Pharmacy: Physical Chemical Principles in the Pharmaceutical Sciences* (4th ed.). Lippincott Williams & Wilkins.

30. Bebber, J. (2025). The Rising Uptake Of Immediate Release And ODT Formulations. *Pharmaceutical Technology*. Retrieved from https://www.pharmtech.com/view/rising-uptake-immediate-release-and-odt-formulations

31. Abbas, F., et al. (2025). Accelerated Medicines Development using a Digital Formulator and a Self-Driving Tableting Data Factory. *arXiv*. Retrieved from https://arxiv.org/abs/2503.17411

32. Capel, A. J., et al. (2018). 3D printing for chemical, pharmaceutical, and biological applications. *Nature Reviews Chemistry*. Retrieved from https://www.nature.com/articles/s41570-018-0002-3